Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Kezar Life Sciences (KZR) Stock Price & Analysis
431 Followers
KZR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.65 - $2.74
Previous Close$0.68
Volume589.23K
Average Volume (3M)693.50K
Market Cap
$49.85M
Enterprise Value-$132.59M
Total Cash (Recent Filing)$201.37M
Total Debt (Recent Filing)$18.93M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 08, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding72,801,359
10 Day Avg. Volume543,035
30 Day Avg. Volume693,499
Standard Deviation0.25
R-Squared0.00222
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-18.94
Enterprise Value/Gross Profit-18.94
Enterprise Value/Ebitda1.27
Forecast
1Y Price Target
$11.00Price Target Upside1506.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsKZR-261 has shown dose-proportional exposure with no signs of accumulation or altered pharmacokinetics.
Financial StabilityFinancial results indicate sufficient funds to operate into the second half of 2026.
Partnerships And LicensingKezar announced an exclusive licensing agreement to develop and commercialize zetomipzomib in several Asian markets.
Bears Say
Financial PerformanceKZR reported a Q4 net loss of $32MM.
Future OutlookShares will remain range bound due to limited near-term catalysts for zeto and skepticism around KZR-261's activity.
RisksRisks include potential negative data releases and failure to advance zetomipzomib in a timely manner.
---
Ownership Overview
21.77% Insiders
12.69% Mutual Funds
40.12% Other Institutional Investors
25.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KZR FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was $0.65 and its highest was $2.74 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Aug 08, 2024 which is in 59 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on May 09, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.033.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -$0.31.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 72,801,360 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went down -6.098%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Wexford Capital LP. It holds Kezar Life Sciences Inc’s shares valued at N/A.
---
Kezar Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (1506.54% Upside)
$11.00 (1506.54% Upside)
Blogger Sentiment
Bullish
KZR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 23.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.49%
12-Months-Change
Fundamentals
Return on Equity
-48.07%
Trailing 12-Months
Asset Growth
-29.93%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
KZR Stock 12 Month Forecast
Average Price Target
$11.00
▲(1506.54% Upside)
Technical Analysis
Adverum Biotechnologies
―
Agios Pharma
―
Arrowhead Pharmaceuticals
―
Axsome Therapeutics
―
Best Analysts Covering KZR
1 Year
1 Year Success Rate
4/14 ratings generated profit
1 Year Average Return
-19.61%
reiterated a buy rating 3 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -19.61% per trade.
---